Related references
Note: Only part of the references are listed.Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia
Betty Lamothe et al.
BLOOD (2015)
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
Zachary A. Hing et al.
BLOOD (2015)
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
Sutapa Sinha et al.
CLINICAL CANCER RESEARCH (2015)
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Fabiola Cervantes-Gomez et al.
CLINICAL CANCER RESEARCH (2015)
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia
Silvia Xargay-Torrent et al.
ONCOTARGET (2015)
Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells
Viralkumar Patel et al.
BLOOD (2015)
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A. Woyach et al.
BLOOD (2014)
The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients
J. Boysen et al.
LEUKEMIA (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
First Axl inhibitor enters clinical trials
Cormac Sheridan
NATURE BIOTECHNOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy
Asish K. Ghosh et al.
BLOOD (2011)
Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy
Karson S. Putt et al.
NATURE CHEMICAL BIOLOGY (2006)
Share Paper
